Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 8/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19204376 | 1.00 | DPP4 (0.46) | DPP4RIPK1DPP7CNR2 | |
| SCHEMBL19204369 | 1.00 | DPP4 (0.46) | DPP4RIPK1DPP7CNR2 | |
| SCHEMBL14892058 | 0.89 | RIPK1 (0.44) | DPP4RIPK1CNR2 | |
| SCHEMBL14162625 | 0.82 | DPP4 (0.43) | DPP4RIPK1DPP7 | |
| SCHEMBL10206063 | 0.82 | DPP4 (0.43) | DPP4RIPK1DPP7 | |
| SCHEMBL12335245 | 0.82 | RIPK1 (0.42) | DPP4RIPK1 | |
| SCHEMBL25927347 | 0.81 | DPP4 (0.43) | DPP4DPP7 | |
| SCHEMBL20976302 | 0.81 | DPP4 (0.40) | DPP4DPP7 | |
| SCHEMBL18427189 | 0.81 | DPP4 (0.40) | DPP4DPP7 | |
| SCHEMBL4311947 | 0.81 | DPP4 (0.44) | DPP4RIPK1DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336773-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180194776-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-12 | — | — | US | disclosed |
| US-9873696-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170320895-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170217959-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-08-03 | — | — | US | disclosed |
| US-9688692-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-27 | — | — | US | disclosed |
| US-9555041-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-20170022219-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-01-26 | — | — | US | disclosed |
| US-20080064718-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022219-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | DPP4 67/4885RIPK1 4473/4885DPP7 83/4885 |
| US-20080064718-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | DPP4 2053/4885RIPK1 614/4885DPP7 1212/4885 |
| US-10336773-B2 | Neprilysin inhibitors | MME, REN, ACE | DPP4 67/4885RIPK1 4473/4885DPP7 83/4885 |
| US-20170320895-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | DPP4 67/4885RIPK1 4473/4885DPP7 83/4885 |
| US-20180194776-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | DPP4 67/4885RIPK1 4473/4885DPP7 83/4885 |
| US-20170217959-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | DPP4 67/4885RIPK1 4473/4885DPP7 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.